Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × AZD 6244 × Endocrine × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4 Dermatologic 2 Breast 2 Sarcoma 1 Other hematologic neoplasm 1 Lymphoid 1 Head & Neck 1 Endocrine 1 CNS 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

Everolimus 8 lutetium Lu 177 dotatate 3 lenvatinib 3 lanreotide 3 fosbretabulin 3 Sorafenib 3 Paclitaxel 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Capecitabine 3 surufatinib 2 pembrolizumab 2 pasireotide 2 gallium Ga 68 dotatate 2 durvalumab 2 dactolisib 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Sunitinib 2 Radiotherapy 2 Panobinostat 2 Octreotide 2 Mitotane 2 Imatinib Mesylate 2 Fluorouracil 2 Filgrastim 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Dexamethasone 2 Adrenalectomy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01843062 2019-08-28

ASTRA

AstraZeneca

Phase 3 Terminated

233 enrolled 14 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡